Start-up gains $30M in Series A funds

With human trials for an experimental Alzheimer's therapy looming, San Diego-based Sonexa Therapeutics has closed its first round of venture funds with $30 million in the bag. Domain Associates, Scale Venture Partners and Alta Partners led the round. Sonexa says that it licensed a development compound to most world markets from a Japanese company. According to the release, the Sonexa team includes president and CMO Sharon Rogers, Ph.D., "who played a leading role in developing Aricept, the top-selling Alzheimer's medication."

- check out the press release

ALSO: Check out the top 20 VC deals of 2007. Report

Related Articles:
Big pharma sees big payback for Alzheimer's research. Report
A new compound to treat Alzheimer's. Report